Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-9549.87%
operating margin TTM
-6014.42%
revenue TTM
1.45 Million
revenue per share TTM
0.05$
valuation ratios | |
|---|---|
| pe ratio | -0.03 |
| peg ratio | -0.00 |
| price to book ratio | -0.02 |
| price to sales ratio | 7.55 |
| enterprise value multiple | 1.61 |
| price fair value | -0.02 |
profitability ratios | |
|---|---|
| gross profit margin | 45.28% |
| operating profit margin | -6014.42% |
| pretax profit margin | -9549.87% |
| net profit margin | -9549.87% |
| return on assets | -246.05% |
| return on equity | 69.92% |
| return on capital employed | 41.19% |
liquidity ratios | |
|---|---|
| current ratio | 0.21 |
| quick ratio | 0.21 |
| cash ratio | 0.09 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 434.22 |
| operating cycle | 474.56 |
| days of payables outstanding | 16,886.19 |
| cash conversion cycle | -16,411.63 |
| receivables turnover | 9.05 |
| payables turnover | 0.02 |
| inventory turnover | 0.84 |
debt and solvency ratios | |
|---|---|
| debt ratio | 3.63 |
| debt equity ratio | -0.90 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | -9.49 |
| interest coverage | -2.59 |
| cash flow to debt ratio | -0.49 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.17 |
| cash per share | 1.05 |
| operating cash flow per share | -4.17 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.49 |
| short term coverage ratios | -0.49 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time BioXcel Therapeutics, Inc. (NASDAQ:BTAI) reported earnings?
BioXcel Therapeutics, Inc. (BTAI) published its most recent earnings results on 13-08-2026.
What is BioXcel Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. BioXcel Therapeutics, Inc. (NASDAQ:BTAI)'s trailing twelve months ROE is 69.92%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. BioXcel Therapeutics, Inc. (BTAI) currently has a ROA of -246.05%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did BTAI's net profit margin stand at?
BTAI reported a profit margin of -9549.87% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is BTAI's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 0.21 in the most recent quarter. The quick ratio stood at 0.21, with a Debt/Eq ratio of -0.90.